Kymera Therapeutics Inc (KYMR) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $95.03
• Market Cap: $7.25B
• EPS: $-3.60
• 52-Week High: $103.00
• 52-Week Low: $19.45

Market Sentiment

Kymera Therapeutics Inc currently has a Bullish sentiment score of 0.16.

About Kymera Therapeutics Inc

Kymera Therapeutics Inc. is a cutting-edge biopharmaceutical firm based in Watertown, Massachusetts, specializing in its proprietary protein degradation technology to transform treatment paradigms. By harnessing the body’s natural protein regulation mechanisms, Kymera develops targeted small molecule therapies aimed at selectively degrading harmful proteins associated with diseases such as cancer and autoimmune disorders. This innovative approach not only differentiates Kymera in the competit...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Kymera Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does KYMR pay dividends?

Kymera Therapeutics Inc (KYMR) does not currently pay a regular dividend.

What is KYMR's market cap?

Kymera Therapeutics Inc (KYMR) has a market capitalization of $7.25B with a current stock price of $95.03.